摘要
目的探讨肾癌患者外周血中CD33+HLA-DR-髓源抑制性细胞(MDSCs)的表达及其与肿瘤分期和病理类型的相关性。方法采用流式细胞术检测肾癌患者(44例)和健康志愿者外周血中CD33+HLA-DR-MDSCs水平,并分析其与肿瘤进展及肿瘤病理类型的相关性。结果肾癌患者外周血中CD33+HLA-DR-MDSCs的表达显著高于健康对照组[(1.91±0.66)%vs(0.62±0.22)%,P<0.001];根据肿瘤分期划分,晚期(Ⅳ期)肾癌外周血CD33+HLA-DR-MDSCs表达明显增高:Ⅰ+Ⅱ期∶Ⅲ期[(1.46±0.44)%∶(2.04±0.35)%,P<0.01];Ⅲ期:Ⅳ期[(2.04±0.35)%∶(2.50±0.64)%,P<0.05];肿瘤患者外周血中CD33+HLA-DR-MDSCs的表达与患者性别和年龄无明显相关性(P>0.05)。结论肾癌患者外周血中CD33+HLA-DR-MDSCs表达与肿瘤分期、分型相关,对肾癌患者的预后及肿瘤免疫方面的研究有显著意义。
Objective To investigate the expression of CD33 ＋ HLA-DR-myeloid-derived suppressor cells（MDSCs） in the peripheral blood of patients with renal carcinoma and its correlation with the clinicopathological features of renal cancer. Methods Forty-four patients with renal carcinoma treated in our hospital between June,2011 and October,2012 and 18 healthy volunteers were enrolled in this study.Flow cytometry was performed to detect CD33 ＋ HLA-DR-MDSCs in the peripheral blood,and its correlation with the clinicopathological features of the patients were analyzed.Results The positivity rate of CD33＋ HLA-DR-MDSCs in the peripheral blood was significantly higher in the cancer patients than in the healthy controls [（1.91 ± 0.66）% vs（0.62 ± 0.22）%,P0.001].The expression levels of CD33 ＋ HLA-DR-MDSCs in patients with renal carcinoma showed significant differences between stage I＋II [（1.46±0.44）%] and stage III [（2.04±0.35）%] patients（P0.01） and between stage III and stage IV patients [（2.50±0.64）%]（P0.05）,but did not differ significantly in respect of age or gender.Conclusion CD33 ＋ HLA-DR-MDSCs expression in the peripheral blood is associated with tumor stage and differentiation in renal carcinoma and may play an important role in predicting the prognosis and tumor immunology of renal carcinoma.
出处
《南方医科大学学报》
CAS
CSCD
北大核心
2013年第4期550-553,共4页
Journal of Southern Medical University
基金
国家自然科学基金(81101559)~~
